ArticleThe Journal of biological chemistry2026
Engineering high-fidelity tapasin variants to enhance MHC-I antigen presentation.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human leukocyte antigen (HLA) proteins are extremely polymorphic, with different allotypes exhibiting a wide range of dependencies on the chaperone tapasin for peptide loading, expression, and stability at the cell surface. Given its central role in antigen processing, tapasin is frequently downregulated across viral infections and cancers, impairing antigen presentation and hindering the identification of therapeutically relevant peptide antigens. We hypothesized that elucidating the mutational tolerance of tapasin surfaces, which mediate interactions with polymorphic HLA residues, can provide a means for fine-tuning its chaperoning function and reveal mechanistic epitopes that underlie its function. Using two complementary deep mutational scanning screens, we systematically mapped the tapasin/HLA-A∗02:01 interaction landscape, highlighting key regions involved in HLA-I assembly and repertoire optimization. We engineered two high-fidelity tapasin variants, tapasin-YTY and tapasin-I2, and show that these variants can increase cell surface HLA expression on a wild-type (WT) tapasin-deficient background by up to 50% and improve peptide-loading function across multiple HLA-A∗ allotypes. Our findings establish scanning mutagenesis as a general approach for fine-tuning chaperone interactions with HLA molecules to enhance antigen presentation in immunologically impaired settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.